Latest Breaking News On - Gain therapeutics inc - Page 24 : comparemela.com

Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α -synuclein levels in vitro and in vivo BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pre-clinical data from its GBA1 Parkinson’s disease program. The findings were highlighted in a presentation at the XXVI International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, a research conference dedicated to Parkinson’s disease and other disorders affecting muscle tone and motor control, being held virtually May 1-4, 2021.

Ricardo feldmanMadeline joanisErici richmanEuropean union horizonGain therapeutics incInternational association of parkinsonismSilverstein foundation for parkinsonLifesci communicationsUniversity of maryland school medicineMichaelj fox foundationPreclinical development of brainWorld congressMichaelj fox foundation for parkinson researchParkinson disease programGain therapeutics presents newDisease program pre clinical